Based on ACR suggestions, allopurinol is strongly encouraged as a first-line urate-reducing medication. Genetic screening is usually recommended (for the variant identified as HLA B*5801) ahead of starting up allopurinol since the carriers of this gene are at a heightened danger of the significant a